EMSA Eritin Blocks Nuclear Factor-Kappa B in Diabetes Mellitus Mice Model
| Main Authors: | Sihombing, Maic Audo Lin, Sumitro, Sutiman B., Rifa'i, Muhaimin |
|---|---|
| Format: | Article info Research application/pdf eJournal |
| Bahasa: | eng |
| Terbitan: |
Postgraduate School, Universitas Brawijaya
, 2015
|
| Online Access: |
https://jels.ub.ac.id/index.php/jels/article/view/161 https://jels.ub.ac.id/index.php/jels/article/view/161/182 |
Daftar Isi:
- Diabetes mellitus is one of the common metabolic disorders with increasing prevalence during recent years with hyperglycemia as its characteristic. DM has been shown to be a state of free radicals over production resulted from hyperglycemia that can activate cellular signaling pathways transcription of factor NF-κB which stimulates the production of several inflammatory mediators andl lead to chronic inflammation. Chronic inflammation is implicated in β-cell damage and function and promotes apoptosis. EMSA Eritin is a polyherbal consisting of soy bean extracts, coconut water extract and red rice extract that assumed to be antidiabetic and anti-inflammatory. This study will assess the effectiveness of EMSA Eritin against inflammation in diabetes mellitus by measuring levels of NF-κB produced by immunocompetent cells in DM mice model. Streptozotocin 100 mg.kg-1 BW is used to induce diabetes mellitus in mice. Oral administration of EMSA Eritin was given for 14 days with dose of 0.3125 mg.g-1 BW, 3.125 mg.g-1 BW and 31.25 mg.g-1 BW. Data were analyzed using One-way ANOVA (p<0.05) and Duncan test using SPSS 16.0 for Windows. The results showed that EMSA Eritin can be used as an alternative therapy for the treatment of DM. The level of NF-κB in diabetic mice significantly decreased when the mice received EMSA Eritin. Keywords: Diabetes Mellitus, EMSA Eritin, NF-κB, ROS